Description of Research Expertise:
My research interests are focused in the genetics of neurodegenerative diseases, in particular frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD). My lab partners with Penn neurologists working in these areas and the Center for Neurodegenerative Diseases for neuropathology and biochemistry to collect DNA from living individuals and brains from autopsy cases to conduct genetic and genome-wide studies to better understand these diseases and identify therapeutic targets. We also work with 2 genetic counselors and have a special interest in the education of patients and the translation of the genetic findings from research labs to CLIA-certified clinical labs so it can benefit patients and families in our research cohort as well as the population at large.
FTLD manifests clinically with progressive behavioral and/or language deficits. Subtypes of FTLD are classified neuropathologically by the protein composition of cellular inclusion bodies. The most common neuropathological correlates of FTLD have TAR DNA binding protein (TDP-43) inclusions (FTLD-TDP) or tau inclusions (FTLD-tau). FTLD is frequently familial and can occur as an autosomal dominantly inherited disorder. Genes with mutations causing FTLD include MAPT (encodes tau) and GRN (encodes progranulin) among others, each of which is associated with a specific FTLD pathological subtype: GRN mutations with FTLD-TDP and MAPT mutations with FTLD-tau. Studying the genetics of FTLD can help elucidate its etiology and pathophysiology and provide targets for therapy as well as identify risk factors that modify disease risk or phenotype. We perform genetic analysis of FTLD, ALS, PD, and AD to identify mutations in known genes as well as novel genes and study them in families to determine pathogenicity, phenotypic variability and correlations with brain pathology. Several recent major projects led to teh identicication of TARDBP (TDP-43) mutations in ALS and a genome-wide association study of FTLD-TDP which identified a novel genetic risk factor, TMEM106B. Many new avenues of research in these areas are being pursued.
Van Deerlin VM, Sleiman PMA, Martinez-Lage M, Chen-Plotkin A, Wang, L-S, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, Arnold SE, Mann DMA, Pickering-Brown SM, Seelaar H, Heutink P, vanSwieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges J, Spillantini MG, Gilman S, Lieberman AP, Kaye JA, Woltjer Randall L, Bigio EH, Mesulam M, Al-Sarraj S, Troakes C, Rosenberg RN, White III CL, Ferrer I, Lladó A,
Neumann M, Kretzschmar HA, Hulette CM, Welsh-Bohmer KA, Miller, BL, Alzualde A, d: Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 42 (3): 234–39,2010.
Chen-Plotkin A,Geser F, Plotkin J, Clark C, Kwong L, Yuan W, Grossman M, Van Deerlin V, Trojanowski J, Lee V: Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum Mol Genet 17 (10): 1349-62,2008.
Chen-Plotkin AS, Xiao J, Geser F, Martinez-Lage M, Grossman M, Unger T, Wood EM, Van Deerlin VM, Trojanowski JQ, and Lee VM.: Brain progranulin expression in GRN-associated frontotemporal lobar degeneration. Acta Neuropath 119 (1): 111-22,2010.
Van Deerlin VM, Leverenz JB, Bekris, LM, Bird TD, Yuan W, Elman LB, Clay D, McCarty Wood E, Chen-Plotkin AS, Martinez-Lage M, Steinbart E, McCluskey L, Grossman M, Neumann M, Wu I-L, Yang W-S, Kalb R, Galasko DR, Montine TJ, Trojanowski JQ, Lee VM-Y, Schellenberg GD, Yu C-E: TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 7 (5): 409-16,2008.
Van Deerlin VM, Wood EM, Moore P, Yuan W, Forman MS, Clark CM, Neumann M, Kwong LK, Trojanowski JQ, Lee VM-Y, and Grossman M: Clinical, genetic, and pathological characteristics of patients with frontotemporal dementia and progranulin mutations. Arch Neurol 64 (8): 1148-53,2007.
Van Deerlin VM, Williams E: Assessment of chimerism in the setting of allogeneic hematopoietic cell transplantation. Molecular Pathology in Clinical Practice, 1st Edition : 517-31,2006.
Jennings LJ, Van Deerlin VM, and Gulley M.: Recommended Principles and Practices for Validating Clinical Molecular Pathology Tests. Arch Pathol Lab Med 133 (5): 743-755,2009.
Talbert ML, Dunn ST, Hunt J, Hillyard DR, Mirza I, Nowak JA, Van Deerlin V, and Vnencak-Jones CL: Competency-Based Education for the Molecular Genetic Pathology Fellow: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diag 11 (6): 497-507,2009.
View all publications